Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.

The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie

J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.

Derek Lewis headshot

Merck Q2 Preview: Double-Digit Earnings Growth in Store?

Year-to-date, Merck shares are well in the green, increasing nearly 20% in value and easily outperforming its Zacks Industry.

Liminal (LMNL) Ends Development of Lead Candidate, Stock Down

Based on results from an early-stage study, Liminal BioSciences (LMNL) decides to discontinue the development of its lead pipeline candidate, fezagepras.

Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie

Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie have been highlighted in this Value Investor article.

Tracey Ryniec headshot

5 Cheap Healthcare Stocks in 2022

Looking for value stocks? Healthcare has been ignored over the last year.

Lantheus (LNTH) to Report Q2 Results: What's in the Cards?

Lantheus' (LNTH) Q2 performance is likely to gain from the continued uptake of PYLARIFY and DEFINITY.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q2 Earnings

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.

Quest Diagnostics (DGX) Tops Q2 Earnings Estimates, Ups View

Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raises its full-year 2022 guidance.

Is a Beat Likely for F5 Networks (FFIV) This Earnings Season?

F5 Networks' (FFIV) Q3 performance is likely to have benefited from the hybrid work environment and the ongoing digital transformation wave, which is boosting the demand for secured communication networks.

Merck's (MRK) Keytruda Head and Neck Cancer Study Fails

Merck's (MRK) phase III KEYNOTE-412 study, evaluating Keytruda in earlier stages of unresected locally advanced head and neck squamous cell carcinoma, disappoints.

Abbott's (ABT) Q2 Earnings Top Estimates, '22 EPS View Up

Abbott (ABT) reports better-than-expected results for Q2 2022, with robust contributions from the Established Pharmaceuticals, Diagnostics and Medical Device segments.

LabCorp (LH) to Offer New Test Report for Venom Allergy Testing

LabCorp's (LH) newly-launched interpretative venom allergy report will inform enhanced treatment decisions in case of venomous insect stings.

AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use

AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.

Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab

Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.

Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.

Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

What's in the Offing for Infosys (INFY) This Earnings Season?

The strong demand for the cloud, data analytics, the Internet of Things and security products and solutions amid the ongoing digital transformation wave is likely to have boosted Infosys' (INFY) Q1 performance.

Molecular Diagnostics Sales to Drive Hologic (HOLX) Q3 Earnings

Hologic's (HOLX) Q3 performance will likely benefit from the increased utilization of Panther instruments and contributions from its recent acquisitions.

Here's Why You Should Retain Chemed (CHE) Stock For Now

Investors are optimistic about Chemed (CHE) owing to the robust demand for Roto-Rooter services and the ongoing rebound in senior housing admissions.

What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?

HCA Healthcare's (HCA) second-quarter results are likely to benefit from better patient volumes. The results might partly suffer from escalating labor costs that might dampen bottom line growth.

GSK Completes Demerger of Consumer Healthcare Business

Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.

Company News for Jul 19, 2022

Companies in The News Are: SYF,DAL,BA,SGEN,MRK,SBUX

J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance

J&J (JNJ) beats estimates for second-quarter earnings as well as sales. It cuts the full-year outlook due to currency headwinds.